Outcomes have improved significantly in multiple myeloma (MM), but racial disparities in health care access and survival exist. A comprehensive analysis exploring MM care and racial disparities is warranted. METHODS: Patients with MM from 1991 to 2010 in the Surveillance, Epidemiology, and End Results-Medicare database were evaluated for racial trends in clinical myelomadefining events (MDEs), the receipt of treatment (drugs and stem cell transplantation; [SCT]), the cost of care, and overall survival (OS). RESULTS: Among 35,842 patients, the frequency of all MDEs at diagnosis increased over time; whereas, in recent years (2006)(2007)(2008)(2009)(2010), all MDEs with the exception of renal dialysis decreased. Blacks had highest rates for all MDEs except bone fractures, which were highest in whites. Over time, the proportion of patients who received any treatment, multiple agents, and SCT increased significantly, and the largest increase was observed in the receipt of immunomodulatory drugs and steroids. There was greater receipt of bortezomib and SCT among whites and blacks and higher receipt of immunomodulatory drugs among Hispanics and Asians (P < .001). Medicare claims were highest during first 6 months after MM diagnosis for blacks and at any time after MM diagnosis for Hispanics. Over time, Medicare claims increased most steadily for Hispanics (P < .001). Hypercalcemia, renal dysfunction, and bone fractures were associated with inferior OS. Blacks and Asians had superior OS compared with whites, but racial differences in OS became less pronounced during 2006 through 2010 (P 5 .182) compared with prior years (P < .01). Better OS was noted among patients who had higher median incomes. CONCLUSIONS: The current results indicate that there have been significant changes in the management of patients with MM over time and provide an in-depth understanding of the factors that may help explain racial disparities.
INTRODUCTION
Multiple myeloma (MM) is the second most common hematologic malignancy, with approximately 30,000 new patients diagnosed in 2017 in the United States. 1 Death rates have been falling over the last decade, with a reported 5-year survival rate of 48.5%. [1] [2] [3] [4] This is mainly because of a rapidly improving therapeutic landscape with novel drugs, better understanding of disease biology, and improvement in supportive care. 3, [5] [6] [7] [8] [9] Despite these encouraging trends, disparities exist in MM outcomes by patient race/ethnicity. 2, 10 Several studies have described these disparities and investigated at their potential causes, and most have reported differences in access to therapeutics options, including novel drugs and stem cell transplantation (SCT). 2, [11] [12] [13] [14] With changing US population demographics and an increasing proportion of racial/ethnic minorities, comprehensive studies describing differences in various aspects of health care among patients according to racial/ ethnic groups are warranted. To be most informative and help shape health care policy to decrease disparities, such studies should focus not only on describing the differences in outcomes and some of the likely causes including health care receipt but also other aspects, including clinical characteristics, management patterns, and economic impact on various racial subgroups. We performed a multifaceted, population-based analysis exploring clinical characteristics at the time of presentation and during disease course, patterns of management, costs of care, and outcomes to understand the true nature of racial/ethnic disparities in MM.
MATERIALS AND METHODS

Data Source
We used data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database with data linkage to Medicare claims (SEERMedicare) (linkage was completed in 2013). 15, 16 The Medicare files we used included the Patient Enrollment and Diagnosis Summary file (PEDSF), the Outpatient file (institutional Medicare Part B claims), the Medicare Provider Analysis and Review file (inpatient Medicare Part A claims), the National Claims History file (provider Medicare Part B claims), Durable Medical Equipment files, and Medicare Part D file (prescription drug coverage for beneficiaries who purchase the benefit; approximately 60% of the beneficiaries). 17 The study received approval from the Institutional Review Board.
Study Population and Variables
All cases of primary MM reported to the SEER cancer registry during the years 1991 through 2010, defined according to the International Classification of Diseases, third edition (the version released September 18, 2015), code 9732 (MM) and microscopic confirmation from positive histology, cytology, or other microscopic method (diagnostic confirmation code, 1-4) were identified. Only patients who had full Medicare coverage (12 months of coverage each year) beginning 1 year before diagnosis through the end of 2012 were included in the analysis. Patients were divided into 5 mutually exclusive racial/ethnic groups (races): non-Hispanic white (white), nonHispanic black (black), non-Hispanic Asian/Pacific Islander (Asian), Hispanic, and Native American, according to the North American Association of Central Cancer Registries (NAACCR) Hispanic/Latino Algorithm (NAACCR Race and Ethnicity Work Group, 2011). 18 Because of small numbers, patients with unknown race and Native-Americans (<0.5%) were not included separately in the statistical analyses. Age and year of diagnosis, race, sex, complications, and date and cause of death were collected. Medical complications of interest were hypercalcemia, renal dysfunction, anemia, bone fracture, and dialysis, (myeloma-defining events [MDEd] ) and were identified by care related to these diagnosis codes. 19 Complications that occurred before or within 30 days of MM diagnosis were defined as complications at diagnosis, and those occurring later were defined as complications after diagnosis. Patients who experienced death within 30 days of diagnosis were excluded from the analysis of complications after diagnosis. MM treatment was collected and summarized as proteasome inhibitor (bortezomib), immunomodulatory drugs (IMiDs) (lenalidomide and thalidomide), cytotoxic agents (melphalan and cyclophosphamide), SCT, and steroids (prednisone and dexamethasone). Data on the use of these modalities were obtained from the Medicare claims files using 5-digit Healthcare Common Procedure Coding System codes and 11-digit National Drug Codes. Because the novel therapeutic agents for MM were not approved by the US Food and Drug Administration throughout the study period, we limited the drug use analysis to 2003 and later, because only the first novel agent (bortezomib) received approval by the US Food and Drug Administration in that year. Medicare insurance claims adjusted for inflation to the year 2013 within the first 6 months of MM care and any time after MM diagnosis were summed and categorized into inpatient, outpatient, and drug charges.
Statistical Analysis
Baseline characteristics and MDE incidence were summarized using frequencies and proportions for categorical variables and median and interquartile ranges for continuous variables. Tests for trends over time in the incidence of each MDE were analyzed using a proportional-odds model with age, sex, and race included as adjustment terms. Associations between MDE incidence and race also were examined using logistic-regression models adjusted for age, year of diagnosis, sex, geographic area according to US Census regions, median income, and education level. Correlations between treatment type, year of diagnosis, and race were analyzed using similar methods. Duration of follow-up was defined as the number of days from MM diagnosis to either loss to follow-up or death. Associations between death from MM and complications before MM diagnosis were assessed using a competingrisk approach. Death from MM was the primary outcome, and competing mortality was treated as the competing event using the Fine and Gray proportional subdistribution hazards model. 20 All MDEs, age, year, sex, and race were fit into single multivariate model. Raceby-MDE and year-by-MDE interactions were fit into separate models to determine whether there were differences in associations of each MDE by race and year. Overall survival (OS) and cumulative incidence curves for myelomaspecific death and competing mortality also were calculated. 21 Univariate associations between the median costs of care within the first 6 months of MM diagnosis or within any time after the diagnosis of MM and the year of diagnosis were performed using Kruskal-Wallis tests. A proportional-odds model was used for multivariate comparisons (adjusted for age, race, and sex), with cost of care categorized into a variable with 11 categories: no charge and deciles. Race-by-cost and year-by-cost interactions also were examined to determine whether there were differences according to these variables. All analyses were performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC), with P < .05 indicating significance.
RESULTS
Study Cohort
In total, 47,608 unique incident cases of MM diagnosed between 1991 and 2010 were identified in the SEERMedicare database. After excluding patients without full Medicare coverage, as defined above, or with missing information on race, 35,842 patients were included in the analysis for the current study (Fig. 1) . For the analysis of MDEs after diagnosis, those who died within 30 days of diagnosis also were excluded, yielding 32,815 cases. (Fig.  1) The median age at diagnosis was 76 years (range, 18-104 years), and the a median follow-up was 1.8 years. The study cohort included 52.1% men (n 5 18,684), with a majority of whites (72%) followed by blacks (16.2%), Hispanics (7.3%), Asians (4.1%), and others (0.3%). MM was the cause of death in 55% of patients, 31% died from other causes, and were 14% lost to follow-up. Age at diagnosis was significantly older for women (median, 77 years) compared with men (median, 75 years; P < .001). The most common MDE before or after MM diagnosis was anemia, which was reported in 17.9% and 25.7% of patients before and after diagnosis, respectively. Overall, 32.4% of patients had a Medicare claim related to the studied anti-MM drugs or SCT.
Myeloma-Defining Events
The incidence of all MDEs at diagnosis increased over time (P < .001), including hypercalcemia, which increased from <0.2% during 1991 to 1995 to 13.2% during 2006 to 2010, and bone fractures, which increased from 6.6% to 19.2% over the same period (Table 1 ). In addition, there were significant linear increases after diagnosis in hypercalcemia and bone fractures during the first 3-year categories, but a decrease was reported from 2006 to 2010 (P < .001). Dialysis requirement had a small but significant increase over time (P < .001). Renal dysfunction and anemia trended toward an increase during the first 3-year categories but decreased from 2006 to 2010, similar to hypercalcemia and bone fractures, although the result from a test for linear trend was insignificant. There were significant differences in all complications at and after diagnosis by race (P < .02) ( Table 1) , with a higher incidence among blacks of all MDEs except bone fractures, which were highest among whites.
Management Modalities
There were significant linear trends in Medicare claims for treatment by year of diagnosis for all treatment agents and for SCT ( Table 2) . Overall treatment increased significantly from 29. In general, the use of single agents even, including bortezomib or IMiDs, decreased over time; and the exposure of patients to multiple agents (3) increased from 18% to 62% in the years from 1991 through 2010 (Fig. 2) . The number of patients who underwent SCT was small in this population; nevertheless, there was a significant increase over time, reaching 14.2% in 2009 and 2010. This may also account for the small but significant increase in melphalan use over recent years. For MM management among racial groups, claims for any treatment were higher among Hispanics (36.5%) and Asians (34.5%) than among whites (32.1%) and blacks (31.6%; P < .001) (Table 2) . Individual drug analyses for trends over time by race could not be performed because of small numbers in some of the subgroups. Overall, whites and blacks had higher use of bortezomib and SCT, whereas Hispanics and Asians had more steroid and IMiD use ( Table 2) .
Cost of Care
Even after adjusting for inflation, the total charges claimed for patients with MM increased significantly by year of diagnosis (Fig. 3A) . Drug claims during the first 6 months after diagnosis increased sharply from median of $230 in 1991 through 1995 to $3630 in 2006 through 2010 (P < .001). Total claims in the same period increased from $5110 to $27,800 (P < .001). Similar sharp increases were noted over time for claims any time after MM diagnosis, with the median claims for drugs only increasing from $1300 to $9900 (P < .001) and total charges increasing from $21,900 to $84,000 (P < .001).
There were significant differences in claims for MM care by race as well (Fig. 3B) . Median drug claims in the first 6 months were highest among blacks ($1300) and lowest among Asians ($630; P 5 .009). The same also was true for total claims in the first 6 months ($15,800 vs $12,300; P < .001). Drug claims any time after MM diagnosis were highest among Hispanics ($5400), followed by Asians ($4700), blacks ($3900), and whites ($3300; P < .001). The median total cost of care any time after MM diagnosis was highest among Hispanics ($62,100), but this was only marginally significant after adjustment for age, year of diagnosis, and sex (P 5 .081). We also noted significant interactions between year of diagnosis and race for Medicare claims (Table 3 , Fig. 3C ). During the first 6 months after diagnosis, claims for drugs increased most steadily among Hispanics (P < .001), whereas total claims increased most among blacks (P < .001). The increase in drug claims any time after diagnosis was greater among Hispanics and Asians than among blacks and whites (P 5 .002). Although there was a substantial increase over time in total claims any time after MM diagnosis for all races (with the greatest increase among Hispanics), the interaction between total overall claims, year of diagnosis, race, and cost of care did not reach a level of significance (P 5 .238).
Overall Survival
The OS rates at 5 years, 10 years, and 15 years were 21%, 6%, and 2%, respectively; and the cumulative incidence of MM-related deaths was 52%, 59%, and 61% 182 ). This made the linear trend of OS for all races over the total study duration nonsignificant (P 5 .22). We also noted a significant improvement in OS with increasing median income level (adjusted to 2000 Census data). When comparing patients with MM who had a median income $34,700 median income (as the reference category) versus those who had a median income of >$61,600, the latter group had a significantly better OS (HR, 0.92; 95% confidence interval, 0.87-0.98; P < .01).
DISCUSSION
There have been substantial improvements in the outcome of patients with MM, and several studies have described factors that may affect the choice of treatment and, ultimately, patient survival. 6, 22, 23 Although previous studies have investigated disparities in outcomes and health care use across races separately, we performed a comprehensive analysis studying clinical presentation, management trends, cost of care, and outcomes in patients with MM across racial subgroups to gain a better understanding of components that are not mutually exclusive when it comes to health care delivery.
Medicare status for each individual is assessed continuously, and the coverage can change from month 
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Cancer April 15, 2018 to month. We only included patients who had continuous Medicare coverage from 1 year before the diagnosis of MM to the end of the follow-up period to avoid lapses in data because of intermittent coverage. Defined exclusions still yielded 35,842 patients, allowing analyses of interactions between clinical and management characteristics. We noted that only a small proportion of patients with MM had claims data for IMiDs or bortezomib, although these agents are used almost universally for all patients with MM. Medicare does not capture supplemental insurance use; therefore, drug claims in this database are lower than otherwise expected. Other groups have also reported similar rates of novel agent use in MM from SEER-Medicare analyses with similar inclusion criteria. 24 To our knowledge no prior report has investigated trends in clinical characteristics, specifically MDEs, in a large cohort of patients with MM over time. We noted that, although the incidence of all MDEs at MM diagnosis increased over time, there was a decreasing trend in all MDEs (except dialysis after diagnosis), some more significant than others, suggesting that better MM therapeutics and supportive care lead to less organ damage and possibly more use of dialysis because of longer survival and a willingness to extend supportive care to more patients. We also noted a higher incidence of MDEs, including hypercalcemia (but not fractures) in blacks at diagnosis as well as any time after MM diagnosis, possibly because of higher baseline and lower age-related decline in bone density in this racial group. 25 This clinical picture, with more MM-related complications in blacks, is contrary to the finding that blacks have better OS than other racial groups and have been postulated to have genetically less aggressive variants of the disease. 2, 26 We do acknowledge the nuance of claims-based database analyses in which changes in billing/coding practices over time may affect the capture rate of various conditions, especially those that are not a patient's primary diagnosis. 
Original Article
To our knowledge, trends in MM management over time, especially for individual drugs, have not been reported previously for Medicare recipients. We noted some expected trends, including a sharp increase in lenalidomide use, which is considered frequently for this population because of its convenience as an oral agent. 27 We also noted an increase in exposure to multiple agents within the first year of MM treatment as well as increased use of SCT, consistent with clinical trial data for the overall population with MM, although most clinical trials have not focused specifically on this patient age group even if it is the most numerous subgroup of patients with MM. 5, 22, 27 This increase in SCT use in the Medicare population is likely because of improved supportive care measures as well as earlier treatment for MM leading to the prevention of organ dysfunction and, hence, eligibility for SCT despite patient age in several cases. We noted significantly different use of treatment overall as well as individual agents for patients of different races. Although these differences can be multifactorial, including geographic, cultural, sociodemographic, economic, and related to access, we adjusted our analyses to several of these factors to account for their effect. Our findings suggest higher Medicare use by Hispanic and Asian patients who have MM compared with whites and blacks, possibly suggesting the role of supplemental insurance, which may be used to a lesser extent because of affordability by racial minorities. Such findings have been reported previously for bortezomib, but never for IMiDs. Understanding this issue is imperative to mitigate disparities in health care access and use among racial subgroups. 28 It is generally believed that the cost of cancer care has increased over time because of more expensive therapeutics, especially novel drugs, and is projected to increase much more in the future. [29] [30] [31] [32] Unlike our current investigation, prior studies have not used a specific cancer model or presented the trends in increasing cost of cancer care. We noted significant increases in the cost of care during first 6 months as well as over the life of a patient for both drug costs and total costs of care. Drug costs made up a small proportion of the total costs. There were significant differences in the cost of care by patient race, in which blacks had the highest drug and total costs in the first 6 months after diagnosis, whereas Hispanics had the highest cost of care for both these categories overall. These differences are not clearly explained by disease presentation or complications, because the patterns are not similar to our analysis of MDEs in these patients. Because only patients who had continuous Medicare coverage were included in our study, and secondary insurance claims are not captured in SEER-Medicare database, our analyses are meaningful because of the uniformity of the patient cohort. This cost-of-care analysis suggests increased health care use by black patients with MM during the first 6 months of diagnosis and by Hispanics overall, possibly secondary to other comorbidities and socioeconomic characteristics. We also noted a higher increase in the cost of care over time especially for drug claims among Hispanics and Asians compared with blacks and whites. These trends are important and should be validated in other, non-Medicare claims-based databases so that the causes of such differences can be better understood and addressed.
Finally, for OS analyses, we were able to confirm previous population-based differences reported among racial subgroups. 2 We noted an inferior survival for women, which is different compared with other population-based MM studies; however, this difference was most likely because of the significantly older age of women in our study cohort. A comparison of early mortality data revealed statistically significant differences among racial groups, but those differences did not appear to be clinically meaningful. Similarly, the association of certain MDEs (including bone fractures and hypercalcemia) with inferior OS in patients who have MM, but no impact on OS of anemia or dialysis at the time of presentation (because of benefit from novel therapeutic agents) has been reported previously, but never in such a large patient cohort. [33] [34] [35] [36] We provide confirmation for the clinical observation that MDEs are associated with inferior OS to a lesser extent in recent years because of better management techniques, including novel therapeutics, earlier initiation of treatment, and improved supportive care. We noted a decrease in the rate of death for those with higher income, which likely demonstrates the effects of access to health care, supplemental insurance coverage, and resource use. We do note an encouraging trend that, in recent years, the differences in OS between patients of different races are becoming less pronounced, in contrast to previous analyses with shorter follow-up in the novel therapeutic era. 2 Health care disparities across races have become an important focus, because they are linked with differential outcomes, and mitigating the factors that lead to these disparities is considered an important goal for health care equity. 2, 28, [37] [38] [39] [40] We report significant trends that are insightful for understanding how the management of MM has changed over time and provide a much more indepth understanding of the factors that may help explain racial disparities. A better understanding and accounting for these factors will ensure that all patients, irrespective of sociodemographic factors, receive benefit from novel therapeutics, health care access, and health care use.
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